In the field of pharmaceutical research, Xiaojie Xu et al.79 reported that miR-30a-5p enhances paclitaxel sensitivity in non-small cell lung cancer through targeting BCL-2 expression. Here, BCL2 is linked to non-small cell lung carcinoma.